Gemphire Therapeutics

About:

Gemphire Therapeutics manufactures and markets Gemcabene, an LDL cholesterol-lowering medication.

Top Investors: Excel Venture Management, CB Health Ventures, Grand Angels

Description:

Gemphire Therapeutics manufactures and markets Gemcabene, an LDL cholesterol-lowering medication. It is a clinical-stage biopharmaceutical company that is committed to helping patients with cardiometabolic disorders, including dyslipidemia and NASH. The company was founded in 2014 and is based in Northville, Michigan.

Total Funding Amount:

$18.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Northville, Michigan, United States

Founded Date:

2014-01-01

Founders:

Charles Bisgaier

Number of Employees:

11-50

Last Funding Date:

2020-01-01

IPO Status:

Private

Industries: